BR112012011467A2 - forma glicosilada de análogo ao glp-1 antigênico. - Google Patents

forma glicosilada de análogo ao glp-1 antigênico.

Info

Publication number
BR112012011467A2
BR112012011467A2 BR112012011467A BR112012011467A BR112012011467A2 BR 112012011467 A2 BR112012011467 A2 BR 112012011467A2 BR 112012011467 A BR112012011467 A BR 112012011467A BR 112012011467 A BR112012011467 A BR 112012011467A BR 112012011467 A2 BR112012011467 A2 BR 112012011467A2
Authority
BR
Brazil
Prior art keywords
analog
glp
glycosylated form
antigenic
antigenic glp
Prior art date
Application number
BR112012011467A
Other languages
English (en)
Inventor
Tezuka Katsunari
Ishii Kazuyuki
Yoshida Kenta
Tsuji Takashi
Kajihara Yasuhiro
Nambu Yuri
Original Assignee
Otsuka Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Chemical Co Ltd filed Critical Otsuka Chemical Co Ltd
Publication of BR112012011467A2 publication Critical patent/BR112012011467A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

forma glicosilada de análogo ao glp-1 antigênico. é revelado um análogo ao glp-1 que é obtido por aperfeiçoamento de um análogo ao glp-1 altamente antigênico, de modo que o análogo ao glp-1 apresentaantigenicidade reduzida sem diminuir sua atividade de supressão da glicose sanguínea. é especificamente revelada uma forma glicosilada do análogo ao glp-1 antigênico, a qual apresenta atividade de glp-1 sendo obtida por substituição de pelo menos um aminoácido de um análogo ao glp-1 antigênico com um aminoácido glicosilado.
BR112012011467A 2009-10-30 2010-10-25 forma glicosilada de análogo ao glp-1 antigênico. BR112012011467A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009249597 2009-10-30
PCT/JP2010/068814 WO2011052523A1 (ja) 2009-10-30 2010-10-25 抗原性ｇｌｐ－１アナログの糖鎖付加体

Publications (1)

Publication Number Publication Date
BR112012011467A2 true BR112012011467A2 (pt) 2019-09-24

Family

ID=43921945

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011467A BR112012011467A2 (pt) 2009-10-30 2010-10-25 forma glicosilada de análogo ao glp-1 antigênico.

Country Status (11)

Country Link
US (1) US20120264684A1 (pt)
EP (1) EP2495255A4 (pt)
JP (1) JPWO2011052523A1 (pt)
KR (1) KR20120101037A (pt)
CN (1) CN102666580A (pt)
AU (1) AU2010312655A1 (pt)
BR (1) BR112012011467A2 (pt)
CA (1) CA2778890A1 (pt)
RU (1) RU2012122162A (pt)
TW (1) TW201119670A (pt)
WO (1) WO2011052523A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2013061818A1 (ja) * 2011-10-25 2013-05-02 国立大学法人岡山大学 新規ペプチド複合体、そのハイブリッド複合体およびその用途
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR102227918B1 (ko) * 2012-11-22 2021-03-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 링커, 당쇄 부가 링커 부분과 생리 활성 물질 부분을 함유하는 화합물 또는 그의 염, 및 이들의 제조 방법
JP6219308B2 (ja) * 2012-11-30 2017-10-25 株式会社糖鎖工学研究所 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法
ES2653765T3 (es) 2012-12-21 2018-02-08 Sanofi Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN111208242A (zh) * 2020-03-24 2020-05-29 东莞市东阳光生物药研发有限公司 利用高效液相色谱法检测glp-1或其类似物的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1231219T3 (da) * 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-lignende peptid-2 analoger
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US7084243B2 (en) * 2000-06-16 2006-08-01 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2451971C (en) 2001-06-19 2010-09-07 Otsuka Chemical Co., Ltd. Process for producing sugar chain asparagine derivative
US20050014681A1 (en) * 2001-11-26 2005-01-20 Yoshiharu Minamitake Medicinal compositions for nasal absorption
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
TWI330641B (en) 2002-12-24 2010-09-21 Yasuhiro Kajihara Sugar chain asparagine derivatives
JP4790271B2 (ja) 2002-12-26 2011-10-12 康宏 梶原 ３分岐型糖鎖アスパラギン誘導体、該糖鎖アスパラギン、該糖鎖およびそれらの製造方法
KR20050095609A (ko) 2003-02-04 2005-09-29 오츠카 가가쿠 가부시키가이샤 당사슬 아스파라긴 유도체의 제조방법
CN1832959A (zh) 2003-03-19 2006-09-13 伊莱利利公司 聚乙二醇连接的glp－1化合物
SG144945A1 (en) 2003-07-28 2008-08-28 Otsuka Chemical Co Ltd Aminated complex-type sugar chain derivatives and process for the production thereof
JP2006095775A (ja) 2004-09-28 2006-04-13 Daiwa House Ind Co Ltd コンクリート板の製造方法およびそれに用いる型枠構造
TWI342880B (en) 2005-07-19 2011-06-01 Otsuka Chemical Co Ltd Method for producing sugar chain derivatives, and sugar chain derivatives
JP2007063907A (ja) 2005-09-01 2007-03-15 Yoshihiko Sano 配水管及び水道栓凍結破裂防止装置
EP1961764B1 (en) * 2005-11-30 2011-05-11 Shionogi Co., Ltd. Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient
JP2008155900A (ja) 2006-12-22 2008-07-10 Sagamihara Shorui Kanri Syst:Kk 水上歩行具
TWI423821B (zh) * 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1 peptide
CA2727147A1 (en) * 2008-06-17 2009-12-23 Otsuka Chemical Co., Ltd. Glycosylated glp-1 peptide

Also Published As

Publication number Publication date
JPWO2011052523A1 (ja) 2013-03-21
TW201119670A (en) 2011-06-16
RU2012122162A (ru) 2013-12-10
EP2495255A1 (en) 2012-09-05
WO2011052523A1 (ja) 2011-05-05
AU2010312655A1 (en) 2012-05-03
CA2778890A1 (en) 2011-05-05
KR20120101037A (ko) 2012-09-12
CN102666580A (zh) 2012-09-12
US20120264684A1 (en) 2012-10-18
EP2495255A4 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
BR112012011467A2 (pt) forma glicosilada de análogo ao glp-1 antigênico.
UY32764A (es) Preparaciones insulinicas que comprenden metionina
BR112016002233A2 (pt) composições de adoçante
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
CL2007001911A1 (es) Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum, en donde la composicion carece de cualquier otro componente proteico del complejo para tratar una afeccion asociada con la inervacion colinergica muscular hiperactiva
GB201020475D0 (en) Delivery mechanism for an autoinjector
BRPI1007010B8 (pt) seringa
CL2015001207A1 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
BRPI1012082A2 (pt) composição aquosa , método para preparar um composição de igg concentrada a partir de plasma , e, uso da composição.
NI201200013A (es) Composición de insulina de acción prolongada
PA8811501A1 (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
MX370264B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
BR112013018704A2 (pt) corpo flutuante anular, e, processo de extinção pelo menos parcial de um movimento de balouço de um corpo flutuante na água
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
AR079821A1 (es) Cepas y metodo para la produccion de metionina
BRPI0923291A2 (pt) processo para a destilação de uma mistura aquosa de polimetilol, composição, e, uso de um polimetilol.
WO2013015579A3 (ko) 콜라겐 및 히알루론산 유도체를 포함하는 의료용 복합 생체 소재
MX2013011833A (es) Formula infantil para ser usada en la prevencion de enfermedades cardiovasculares.
BR112013016521A2 (pt) isolador tendo montagem de soquete
BR112012023912A2 (pt) produto de artigos de confeitaria contendo componentes ativos e/ou reativos e métodos de produção do mesmo
BR112017008134A2 (pt) máquina de fresagem, e, molde.
BR112012027550A2 (pt) uso de uma composição
PH12014502071A1 (en) Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: OTSUKA CHEMICAL CO., LTD (JP)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO 020130068036 DE 02/08/2013 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2559 DE 21/01/2020.